$205.24
+0.06%Price chart
Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15
Key dataSep 15, 2026
Open$206.98
From 52W high−7.19%
Volume1.22M
Market cap$43.99B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 15, 2026
Open
$206.98
From 52W high
−7.19%
Volume
1.22M
Market cap
$43.99B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−24.0x
P/E (TTM)
—
RSI (14)
47.6
MomentumView details →
1D Return
+0.06%
YTD Return
+155.05%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company went public in February 2020 and focuses specifically on developing novel therapies to treat RAS-addicted cancers. RAS proteins are among the most frequently mutated oncogenes in human cancers, found in approximately 30% of all cancers and up to 95% in certain cancer types like pancreatic cancer. Revolution Medicines has built a comprehensive pipeline of RAS pathway inhibitors and is currently advancing multiple drug candidates through clinical trials, with its lead program entering Phase 3 pivotal trials.
Similar companies
Latest newsMore news →
The U.S. FDA granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma.2d agoThe FDA approved a pill from Revolution Medicines to treat late-stage prostate cancer.11d agoRevolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.14d ago